Pancreatic safety of sitagliptin in the TECOS Study.
<h4>Objective</h4> <p>We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i).</p> <h4>Research Design and Methods</h4>...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Diabetes Association
2016
|